Abstract
Medullary thyroid cancer (MTC) is a rare subtype of thyroid cancer characterized by a high frequency of molecular alteration (MA) in the RET oncogene. Recently, Ret specific inhibitors (RETi) have emerged as an effective treatment in phase I/II trial. However, resistance almost invariably occurs.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
